Seungkyu Lee, Yoonji Kim, Seung Keun Back, Hee-Woo Choi, Ju Yeon Lee, Hyun Ho Jung, Jae Ha Ryu, Hong-Won Suh, Heung Sik Na, Hyun Jeong Kim, Hyewhon Rhim, Jae Il Kim
Index: Mol. Pain 6 , 97, (2010)
Full Text: HTML
N-type Ca2+ channels (Ca(v)2.2) play an important role in the transmission of pain signals to the central nervous system. ω-Conotoxin (CTx)-MVIIA, also called ziconotide (Prialt®), effectively alleviates pain, without causing addiction, by blocking the pores of these channels. Unfortunately, CTx-MVIIA has a narrow therapeutic window and produces serious side effects due to the poor reversibility of its binding to the channel. It would thus be desirable to identify new analgesic blockers with binding characteristics that lead to fewer adverse side effects.Here we identify a new CTx, FVIA, from the Korean Conus Fulmen and describe its effects on pain responses and blood pressure. The inhibitory effect of CTx-FVIA on N-type Ca2+ channel currents was dose-dependent and similar to that of CTx-MVIIA. However, the two conopeptides exhibited markedly different degrees of reversibility after block. CTx-FVIA effectively and dose-dependently reduced nociceptive behavior in the formalin test and in neuropathic pain models, and reduced mechanical and thermal allodynia in the tail nerve injury rat model. CTx-FVIA (10 ng) also showed significant analgesic effects on writhing in mouse neurotransmitter- and cytokine-induced pain models, though it had no effect on acute thermal pain and interferon-γ induced pain. Interestingly, although both CTx-FVIA and CTx-MVIIA depressed arterial blood pressure immediately after administration, pressure recovered faster and to a greater degree after CTx-FVIA administration.The analgesic potency of CTx-FVIA and its greater reversibility could represent advantages over CTx-MVIIA for the treatment of refractory pain and contribute to the design of an analgesic with high potency and low side effects.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
ω-Conotoxin MVIIA
CAS:107452-89-1 |
C102H172N36O32S7 |
The effect of spider toxin PhTx3-4, ω-conotoxins MVIIA and M...
2011-03-01 [Cell. Mol. Neurobiol. 31(2) , 277-83, (2011)] |
Rationale for Prospective Assays of Intrathecal Mixtures Inc...
2015-01-01 [Pain Physician 18 , 349-57, (2015)] |
Prolonged delirium with psychotic features from omega conoto...
2013-03-01 [Pain Med. 14(3) , 447-8, (2013)] |
[Neuropsychiatric side effects of intrathecal ziconotide].
2011-01-01 [Rev. Neurol. 52(1) , 61-3, (2011)] |
Ziconotide combination intrathecal therapy: rationale and ev...
2010-09-01 [Clin. J. Pain 26(7) , 635-44, (2010)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved